Understanding how cells clear harmful proteins and RNA in conditions like ALS
Analysis of mRNP granule clearance, vacuolar RNA decay and TDP-43 turnover
This project looks at how cells clean up specific protein and RNA clumps, which could help us understand diseases like ALS.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-11087512 on NIH RePORTER |
What this research studies
Our cells have natural ways to clean up unwanted materials, like protein and RNA clumps called mRNP granules, to stay healthy. When these cleanup processes don't work correctly, these clumps can build up and become toxic, as seen in conditions like Amyotrophic Lateral Sclerosis (ALS). This work explores the different ways cells get rid of these harmful materials, including a protein called TDP-43, which is known to cause problems in ALS when it misbehaves. By figuring out these cellular cleanup systems, we hope to uncover new ways to protect brain cells from damage. We are particularly interested in how stress granules and TDP-43 are cleared, as their malfunction is linked to neuron toxicity.
Who could benefit from this research
Good fit: This foundational research is not directly recruiting patients but could eventually benefit individuals with neurodegenerative conditions like ALS, where protein and RNA clumps accumulate.
Not a fit: Patients seeking immediate treatment options or direct clinical intervention would not find direct benefit from this basic science project.
Why it matters
Potential benefit: If successful, this work could reveal new targets for therapies that help cells clear toxic proteins and RNA, potentially slowing the progression of diseases like ALS.
How similar studies have performed: While the specific mechanisms of mRNP granule and TDP-43 clearance are still being uncovered, other basic science efforts have shown the importance of cellular cleanup pathways in neurodegenerative diseases.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Buchan, John Ross — University of Arizona
- Study coordinator: Buchan, John Ross
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.